Sprout BioVentures

Sprout BioVentures invests in early-stage opportunities that turn insights from human biology into workable therapies. The firm holds that no drug target is truly out of reach, only not yet tackled.

Services

• Early-stage investment: funding for promising therapeutic opportunities.
• Drug development expertise: help building chemical equity strategies and finding strong candidates for clinical proof of concept.
• Genetics-led target selection: a preference for targets that emerge from population-wide genetic association studies, where loss-of-function or gain-of-function mutations point to a treatment approach.

Clients

The firm is drawn to targets backed by human genetic evidence rather than to new technology platforms. Its partners bring a background in biopharmaceutical research, clinical trials and drug discovery, including earlier roles at large pharmaceutical companies and a research institute.

Key facts

• Focus: Human genetics-backed therapeutics
• Stage: Early-stage
• Partners: Brian Hubbard, Dan Meyers and Michael Serrano-Wu